Clinical Trial and Option Agreement with CRUK and CIRM Grant Award
September 2014, Asterias entered into a Clinical Trial and Option Agreement (the “CRUK Agreement”) with Cancer Research
UK (“CRUK”) and Cancer Research Technology Limited, a wholly-owned subsidiary of CRUK, pursuant to which CRUK has
agreed to fund Phase 1 clinical development of Asterias’ human embryonic stem cell derived AST-VAC2 allogeneic (non-patient
specific) dendritic cancer vaccine product candidate. Asterias, at its own cost, completed process development and manufacturing
scale-up of the AST-VAC2 manufacturing process and transferred the resulting cGMP-compatible process to CRUK. CRUK will, at its
own cost, manufacture clinical grade AST-VAC2 and will carry out the Phase 1 clinical trial of AST-VAC2 in cancer patients both
resected early-stage and advanced forms of lung cancer. Asterias will have an exclusive first option to obtain a license to use
the data from the clinical trial. If Asterias exercises that option, then Asterias will be obligated to make payments upon the
execution of the License Agreement, upon the achievement of various milestones, and royalties on sales of products. In connection
with the CRUK Agreement, Asterias sublicensed to CRUK for use in the clinical trials and product manufacturing process certain
patents that have been licensed or sublicensed to it by third parties. Asterias would also be obligated to make payments to those
licensors and sublicensors upon the achievement of various milestones, and then royalties on sales of products if AST-VAC2 is
successfully developed and commercialized.
October 16, 2014 Asterias signed a Notice of Grant Award (“NGA”) with CIRM, effective October 1, 2014, with respect
to a $14.3 million grant award for clinical development of Asterias’ product, AST-OPC1. The NGA was subsequently amended
effective November 26, 2014 and March 2, 2016. The NGA includes the terms under which CIRM will release grant funds to Asterias.
Under the NGA as amended on March 2, 2016, CIRM disbursed the grant funds to Asterias based on Asterias’ attainment of certain
received an initial payment from CIRM in the amount of $917,000 during October 2014 and had received $12.8 million through December
31, 2016. In September 2017, Asterias received the final $1.5 million payment under the CIRM grant which was due upon achievement
of certain progress milestones. Asterias had no deferred grant income relating to the CIRM grant as of September 30, 2018 and
December 31, 2017. Asterias recognized no grant income for the three and nine months ended September 30, 2018 and $1.5 million
and $3.7 million in grant income for the three and nine months ended September 30, 2017, respectively.
November 7, 2018, we entered into a definitive agreement with BioTime, pursuant to which BioTime will acquire all of our outstanding
shares that BioTime does not already own, in a stock-for-stock transaction pursuant to which our shareholders will receive 0.71
common shares of BioTime for every share of our common stock. Following the transaction, our shareholders will own approximately
16.2% of BioTime, based on the number of BioTime shares outstanding on November 7, 2018. If the transaction is consummated, we
would cease to exist as a public company and BioTime will consolidate our operations and results with its consolidated results
beginning upon the consummation of the transaction. The transaction is subject to certain customary closing conditions, including
approval of our shareholders, as well as the shareholders of BioTime.